NCT05986721View on ClinicalTrials.gov

Clinical Trial of AGB101 for Mild Cognitive Impairment

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 3, 2024

Primary Completion Date

July 31, 2028

Study Completion Date

December 31, 2028

Conditions
Mild Cognitive ImpairmentProdromal Alzheimer's Disease
Interventions
DRUG

AGB101

low-dose levetiracetam, 220 mg, extended release tablet

DRUG

Placebo

Placebo oral tablet

Trial Locations (1)

21287

Johns Hopkins, Baltimore

Sponsors

Lead Sponsor

AgeneBio
All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

AgeneBio

INDUSTRY

NCT05986721 - Clinical Trial of AGB101 for Mild Cognitive Impairment | Biotech Hunter | Biotech Hunter